Comparative Pharmacology
Head-to-head clinical analysis: NILOTINIB HYDROCHLORIDE DIHYDRATE versus PEMAZYRE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILOTINIB HYDROCHLORIDE DIHYDRATE versus PEMAZYRE.
NILOTINIB HYDROCHLORIDE DIHYDRATE vs PEMAZYRE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nilotinib is a BCR-ABL tyrosine kinase inhibitor that binds to and stabilizes the inactive conformation of the ABL kinase domain, thereby inhibiting proliferation and inducing apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
Selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4; binds to and inhibits FGFR kinase activity, leading to decreased tumor cell proliferation and angiogenesis.
400 mg orally twice daily, approximately 12 hours apart, without food (at least 2 hours before or 1 hour after a meal).
13.5 mg orally once daily continuously until disease progression or unacceptable toxicity.
None Documented
None Documented
Approximately 17 hours (terminal elimination half-life; supports once-daily or twice-daily dosing; extensive accumulation with daily dosing, steady state by day 8)
Terminal elimination half-life is approximately 20 hours (range 14–32 h), supporting once-daily dosing with steady-state reached within 8 days.
Fecal (93%), renal (3%; unchanged nilotinib appears minimal, mostly metabolites)
Primarily hepatobiliary excretion: 72% of the dose recovered in feces (mainly as unchanged drug and metabolites); renal excretion accounts for approximately 17% (less than 1% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor